Discover investment opportunities in Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharma Stocks To Buy using our Smart AI Filter.
10 stocks found for "Pharma Stocks To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.45 | ±25.0% | 14.4 | 3.19% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read moreQ: How does Pfizer's (PFE) current valuation compare within the pharmaceutical sector?
A: Pfizer's valuation, measured by its P/E ratio, provides a benchmark against other pharma stocks like Merck (MRK) and Johnson & Johnson (JNJ). As valuations fluctuate with market conditions, investors often look at growth potential and pipeline developments for context.
Q: What recent developments in Merck's (MRK) pipeline should investors watch?
A: Merck's pipeline includes significant advancements in oncology, particularly with Keytruda, their leading immunotherapy product. Success in clinical trials and FDA approvals can impact future earnings projections.
Q: Are dividends from Eli Lilly (LLY) stocks considered reliable for income-focused investors?
A: Eli Lilly has a history of consistent dividend payments. However, investors should review the dividend payout ratio and any recent financial statements to assess reliability amid changing market dynamics.
Q: How do competitive advantages influence the growth prospects for Vertex Pharmaceuticals (VRTX)?
A: Vertex Pharmaceuticals holds significant competitive advantage in cystic fibrosis treatments, driving revenue growth. However, reliance on a narrow drug portfolio can pose risks without development in other therapeutic areas.
Q: What economic cycles affect Bristol-Myers Squibb's (BMY) stock performance?
A: Bristol-Myers Squibb's performance is partly influenced by economic cycles impacting healthcare budgets and pharmaceutical pricing. Historical resilience during downturns is noted, but healthcare reforms can alter dynamics.
Q: What are common risks associated with investments in Regeneron Pharmaceuticals (REGN)?
A: Regeneron faces risks such as high R&D costs, dependency on EYLEA for revenue, and potential competition from biosimilars. Strategic partnerships and innovation may help mitigate these factors.